When many people contemplate the euphoria induced by marijuana consumption, their thoughts inevitably gravitate toward THC, the plant’s principal psychoactive constituent. However, a recent study lends support to the notion of the “entourage effect,” demonstrating that marijuana products containing a wider variety of natural cannabinoids result in an even more potent psychoactive high than those made from pure THC.

This research used innovative electroencephalogram (EEG) technology, augmented by AI capabilities, to gauge the euphoria that individuals experienced while vaporizing two distinct products. The first was a full-spectrum live rosin with an average concentration of 85% THC, complemented by other natural terpenes and cannabinoids. The second was a high-purity THC oil boasting a potency range of 82% to 85%.

Twenty-eight adults took part in the study, donning EEG headsets created by the marijuana technology company Zentrela. The participants ingested two hits (8 mg) of the first or second product through a vape made by PAX, which also sponsored the research.

Before consuming the products, the participants underwent a baseline reading. Over the ensuing 90 minutes, the EEG observed cerebral activity across eight distinct brain regions. Subsequently, the collected data were translated into psychoactive effect levels (PEL), which are expressed on a standard scale ranging from 0% to 100%. The outcomes unveiled that the full-spectrum live rosin, containing THC along with other terpenes and cannabinoids, exhibited a slightly swifter onset: three minutes. Results showed a potency reading of 20.8% at the outset and even more substantial potencies at the 15-minute peak (40%) and 90-minute mark (30.2%).

On the other hand, the pure THC product exhibited an average onset time of four minutes with an initial potency of 13.5%. At its peak, the potency registered at 19.1%, subsequently declining to 18.1%.

In essence, the study, while yet to undergo peer review or publication in a scientific journal, lends credence to the entourage effect hypothesis. It suggests that cannabis containing a more varied composition of its innate constituents yields a more potent experience. This finding holds significance for patients, as the entourage effect could potentially fortify specific therapeutic applications.

Brian Witlin, PAX’s vice president of product development, stated in a press release, “Consumers seeking psychoactive effects frequently base their choices on THC content, which is somewhat misleading.”

Beyond enhancing consumer awareness, the study’s findings can also empower marijuana companies to devise more targeted products by harnessing data regarding the distinct combinations of cannabinoids that engender diverse effects.

This study isn’t the first to spotlight the comparative advantages of diverse marijuana products. In 2018, a study revealed that patients with epilepsy who utilize plant-based CBD extracts as opposed to refined CBD products have better health results and experience fewer negative side effects.

For companies that sell whole-flower products, such as SNDL Inc. (NASDAQ: SNDL), the study’s findings that the entourage effect triggers more intense experiences for cannabis users makes a case for the continued development of products that leverage the entire spectrum of cannabinoids and other constituents rather than individual compounds.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Srettha Thavisin, Thailand’s newly elected prime minister, has pledged to change the country’s cannabis laws over the next six months to limit their use to medical purposes only. Thailand became the first Asian country to decriminalize marijuana after delisting the plant as a narcotic last year, resulting in a surge of cannabis dispensaries and cafes in major tourist locations such as Pattaya, Chiang Mai and Bangkok.

Currently, Thai law allows adults over the age of 20 to use marijuana inside their homes but not while they are nursing or pregnant. Furthermore, foods containing cannabis extracts are permitted to be served in restaurants with a license.

However, the lack of legislation to govern its usage has resulted in a legal gap in the country. Presently, about 6,000 dispensaries are operating nationwide, offering a range of cannabis products from oil extracts to buds. Thai farmers have also been permitted to cultivate marijuana after registering with the Thai FDA.

Thailand’s new leader, who took office in August, stressed the consensus within the coalition government to amend the law and prohibit recreational use. “The law must undergo a complete overhaul,” Srettha stated. “It needs correction. We can only control it for medical use,” he added, dismissing any compromise for recreational usage.

Srettha is the leader of the Pheu Thai Party, which formed a coalition government with 10 other parties. Prior to the May elections, the coalition advocated for a strict antidrug campaign and pledged to undo the historic cannabis decriminalization policy. The coalition includes the Bhumjaithai Party, led by Anutin Charnvirakul, who remains committed to advancing a parliamentary bill aimed at introducing stricter industry oversight while opposing the reclassification of marijuana as a controlled substance.

Some within the tourism sector have welcomed the move to restrict cannabis usage, citing problems arising from lax industry regulations. Thanet Supornsahasrungsi, group executive director of Sunshine Hotels and Resorts in Pattaya, remarked that most marijuana shops largely cater to recreational users and that there have been reports of marijuana overdoses. He emphasized the importance of stricter regulations to ensure that individuals who need it receive safe medical care.

Supporters of recreational cannabis argue that reclassifying the substance as a narcotic instead of implementing industry regulation, could drive recreational usage into an unregulated underground market, exacerbating control issues. Thailand plays a key role in drug trafficking along the vast Mekong River valley in southeast Asia, often with the assistance of law enforcement agencies. Srettha has committed to eliminating illicit drugs in the nation within a year.

This policy reversal is obviously disturbing to companies that were investing in the industry in anticipation that enabling regulations would be enacted. Even established companies such as SNDL Inc. (NASDAQ: SNDL) would be immensely impacted if any of the markets in which they had advanced plans to expand into suddenly changed course and reestablished prohibitive policies.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Activists in Nebraska have initiated a fundraising campaign to garner support for the inclusion of two medical cannabis legalization proposals on the state’s 2024 ballot. The group, Nebraskans for Medical Cannabis (NMM), has already begun the circulation of petitions and claims to have satisfied signature requirements in two counties by the end of last month.

The recent launch event held in Lincoln aimed to address a significant hurdle faced last year: the loss of vital funding after a major donor’s tragic death in a plane crash.

This is the third attempt by NMM to present the reform proposal to voters, and activists maintain their optimism, believing they will secure the necessary grassroots backing and resources to succeed this time around.

The launch showcased the involvement of various caregivers, patients and activists in medical marijuana advocacy, including key figures such as Crista Eggers, the campaign manager, and Senator Anna Wishart and former Senator Adam Morfeld, both of whom cochair NMM.

The campaign is set to obtain signatures from at least 5% of registered voters in 38 counties by year-end, with two counties already accomplished. To secure a place on the November 2024 ballot, the campaign must collect approximately 87,000 valid signatures from registered voters for each petition, in addition to meeting the county-specific goals, by July 5, 2024.

One of the initiatives seeks to establish safeguards for doctors recommending cannabis and patients purchasing and possessing it, effectively creating qualified immunity. The second initiative plans to establish a state cannabis commission to oversee the registration and regulation of individuals involved in the production, distribution and dispensing of medical cannabis.

Governor Jim Pillen has voiced opposition to marijuana reform, asserting that medical cannabis should only be accessible through FDA-approved processes, citing potential risks to children. In contrast, Eggers, NMM’s campaign manager, is determined to advocate for children such as her son, who suffers from severe seizures and could benefit from medical cannabis.

NMM initially submitted its reform petitions in May, with signature collection starting in July. An earlier campaign secured enough signatures for the 2020 ballot but was invalidated by the state Supreme Court due to a single-subject challenge. Subsequently, the revised petitions fell short due to a lack of funding following the tragic plane crash that claimed a key donor’s life.

Efforts by Nebraska legislators, including Wishart, to enact marijuana reform legislatively have consistently faced hurdles in the conservative legislature. Despite receiving a hearing in the unicameral Judiciary Committee in February, Wishart’s medical marijuana bill did not progress, which she attributed to changes in committee membership. A prior version of the measure faced a filibuster and ultimately stalled in the GOP-controlled legislature.

As many more states and countries work to ease their marijuana regulations, companies such as SNDL Inc. (NASDAQ: SNDL) will have a bigger pool of potential markets into which to expand as they grow their footprints.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

New data from Health Canada has revealed that Australia and Israel were the top buyers of Canada’s medical marijuana exports in 2022. Figures shared through MJBizDaily show that the two nations were the largest markets for Canadian medical cannabis importers amid a surge in cannabis exports from Canada.

Medical cannabis flower exports from the North American nation totaled around 132,200 pounds for fiscal year April 2022 through March 2023 and went up by 48% from the previous fiscal year’s roughly 90,000 pounds. Close to 80% of medical marijuana flower exports from Canada (104,000 pounds) went to Australia and Israel and 16% (21,000 pounds) went to Germany.

Canada has exported 277,000 pounds (126,025 kilograms) of medical marijuana flower for commercial and scientific use since 2017, MJBizDaily reports. The value of Canada’s medical marijuana exports in 2022 also increased by 50% from the fiscal year 2021–2022 to around $118 million. However, while players in the cannabis industry are likely pleased with the increased international demand for their cannabis flower, relying on three nations for the majority of exports puts the Canadian medical marijuana export segment at significant risk.

According to Miguel Martin, the CEO of Edmonton, Canada, cannabis producer Aurora Cannabis, investing in medical marijuana flower exports is a “long-term play.” He noted that export margins are 2.5 times higher than margins in the local recreational marijuana market and are “not declining.”

Although Australia and Israel were both major importers of Canadian medical cannabis flower, Australia imported most of Canada’s cannabis extracts in 2022. Of the 2,388 gallons of medical cannabis extract Canada exported last year, 2,217 gallons went to Australia followed by the Cayman Islands at 845 gallons, and Brazil, Barbados and South Africa at 35 gallons, 27 gallons and 23 gallons respectively.

Cannabis producers in Canada have become increasingly focused on the international market due to higher margins compared to the Canadian market, which is plagued with issues such as oversaturation and oversupply. Additionally, excise taxes levied by Canadian authorities on cannabis products reduce margins for cannabis producers in local markets and incentivize them to seek business partnerships with buyers in other nations.

Thanks to significantly reduced competition in foreign markets such as Israel and Australia, Canadian medical cannabis exporters don’t have to worry about sharing their market with an increasing number of sellers. However, nations such as Denmark and Columbia are becoming increasingly relevant in the global cannabis trade and may soon begin eating into Canada’s market share. Companies such as SNDL Inc. (NASDAQ: SNDL) therefore have to step up their innovativeness even more in order to stay ahead of the competition.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

A recent study published in the “Cancer” Journal explores the potential advantages of utilizing cannabis for children undergoing cancer treatment, a group that contends with various symptoms resulting from the disease and its therapies. However, while promising, further exploration into appropriate dosing and safety is imperative.

Advances in diagnostics, surgery and radiation have elevated survival rates among pediatric cancer patients. Nevertheless, progress brings its own set of issues, including anorexia, pain, vomiting and nausea, which prove challenging to manage. Cannabis derivatives have emerged as a strategy to alleviate these symptoms in young cancer patients. However, its safety, effectiveness and dosing in this demographic remain largely uncharted.

The authors of the study note that “pediatric oncologists remain cautious about cannabis due to the dearth of substantiated evidence affirming its safety and efficacy within this context. There’s an urgency to comprehensively examine the current landscape of cannabinoid application in pediatric cancer, guiding the evolution of clinical trials scrutinizing the impact of diverse cannabis products on safety, dosing, and efficacy for this demographic.”

Researchers from the University of Manitoba undertook a systematic meta-analysis and review to evaluate the body of literature concerning the use of medicinal marijuana for alleviating symptoms in pediatric cancer cases. They drew upon resources such as the Cochrane Library, PsycINFO, Embase and MEDLINE.

A total of 34,611 citations were examined, involving various cannabis strains, quantities, forms, administration methods and indications, as well as clinical and demographic attributes. These citations also encompass documented efficacy outcomes and any resultant unfavorable incidents. From those, 19 studies along with 1,927 participants were considered suitable for the study.

Within these studies, diverse marijuana products emerged as potential solutions for tackling distinct symptoms. Primarily, cannabis demonstrated efficacy in countering chemotherapy-induced vomiting and nausea. The side effects linked to cannabis usage include dry mouth, drowsiness and vertigo. Importantly, none of the studies documented any severe adversities linked to cannabis use in alleviating cancer-related symptoms in pediatric patients.

Lead author Lauren E. Kelly, PhD, acknowledged the challenges in measuring overall advantages due to disparate outcomes and study designs. Kelly noted, “While interventions with active control groups showed the superiority of cannabinoids in countering nausea and vomiting, data scarcity persists concerning cannabinoids’ influence on sleep, mood, pain, and the holistic quality of life.”

The study’s limitations included the count of studies within the review, outcome reporting inconsistencies, and the absence of case-controlled or cohort studies in the analysis.

Kelly emphasized the pivotal importance of conducting more rigorous investigations into the effects of cannabinoids on pediatric cancer patients and sharing such findings with the healthcare sector, patients and parents, given the varying experiences reported by children in terms of benefits and adverse events.

As more information becomes available regarding the therapeutic potential of cannabis for specific groups or demographics of patients, marijuana companies such as SNDL Inc. (NASDAQ: SNDL) could tweak their products in order to avail the most suitable product to address the specific symptoms of those patients.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN